The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE Ibrance (palbociclib) regimen for ...

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer ...

Pfizer (PFE) stock is in focus as the FDA approves a label expansion therapy for breast cancer therapy, palbociclib, marketed ...

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its cl ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...

Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous ...

Pfizer's new approval for Ibrance bucked regulatory norms in more ways than one. (VIEW press/Corbis News/Getty Images) It’s unusual to have the FDA chase down a pharma company and ask them apply for a ...

On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...